ChemotherapyFDA-approvedFirst-line
Folfox
Generic name: oxaliplatin
How it works
Interferes with DNA replication, causing cancer cells to die. Also, it can cause blood vessels to form in tumors, making them more visible to the immune system.
Cancer types
Colorectal Cancer— All patients
Efficacy
Studies show that Folfox can improve overall survival and response rates in patients with metastatic colorectal cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Chemo-Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing BOLD-100 in Combination with FOLFOX for Advanced Solid Tumors | Colorectal Cancer | phase-1 | — | Source → |
| Rectal Cancer Trial Examines New Treatment Combination | Colorectal Cancer | phase-2 | — | Source → |
| Testing a New Combination Therapy for Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly Patients | Colorectal Cancer | phase-2 | — | Source → |
| Testing Ivonescimab and Bevacizumab in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Preventing Nerve Damage in Cancer Patients | Colorectal Cancer | preclinical | — | Source → |
| New Treatment Combination Shows Promise for Colon Cancer Patients | Colorectal Cancer | phase-3 | The 3-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group, as compared with 76.2% in the mFOLFOX6 group. | Source → |
| Nicotine Affects Colon Cancer Treatment Efficacy | Colorectal Cancer | lab-study | — | Source → |
| Blueberry Anthocyanins Enhance Chemotherapy Effectiveness in Colon Cancer Cells | Colorectal Cancer | lab-study | The combination of blueberry anthocyanins and oxaliplatin significantly inhibited the proliferation and colony formation of HCT116 and LOVO cells (P<0.01) and markedly suppressed tumor growth in the nude mouse xenograft model (P<0.05). | Source → |
| New Diagnostic Tool for Colorectal Cancer Identified | Colorectal Cancer | lab-study | The diagnostic signature demonstrated robust performance in distinguishing resistant cases (AUC = 0.868). | Source → |
| Oxaliplatin-resistant colorectal cancer cells linked to specific proteins | Colorectal Cancer | lab-study | Silencing CHGA and UCHL1 genes effectively suppressed the mobility and invasiveness of OXA-resistant HCT-116/OxR cells while promoting G1 phase cell cycle arrest and reducing ROS production and intracellular calcium concentrations. | Source → |
| Comparing Second-Line Treatments for Pancreatic Cancer | Pancreatic Cancer | observational | 5-FU + Nal-IRI showed a median overall survival of 7.2 months, compared to 5.8 months for FOLFOX/XELOX. | Source → |
| Adding Panitumumab to Chemotherapy for Colon Cancer | Colorectal Cancer | phase-2 | There was a trend towards reduced recurrences with FOLFOX plus panitumumab compared with FOLFOX (12% versus 21%, hazard ratio = 0.51, P = 0.09) | Source → |
| LAMA3 Gene May Help Colon Cancer Respond Better to Oxaliplatin | Colorectal Cancer | lab-study | — | Source → |
| FOLFOX Chemotherapy Linked to Severe Potassium Deficiency | Colorectal Cancer | observational | — | Source → |
| Comparing Chemotherapy Options for Colorectal Cancer | Colorectal Cancer | phase-3 | Ox resulted in a significantly improved peritoneal recurrence-free survival in CC0/1 patients (MMC=9.0 versus Ox=12.6months, P = .01). | Source → |
| Long non-coding RNA linked to oxaliplatin resistance in colorectal cancer | Colorectal Cancer | lab-study | — | Source → |
| Oxaliplatin Side Effect Study in Colorectal Cancer Patients | Colorectal Cancer | phase-3 | — | Source → |
| New Treatment Shows Promise for Colorectal Cancer Patients | Colorectal Cancer | phase-1 | Compared with standard therapy, PIPAC-Oxaliplatin was associated with higher median good days at 6 months (181 vs 131 days; p = 0.042) and 1 year (323 vs 131 days; p = 0.032), and longer overall survival (median, 11.3 vs 5.1 months; p = 0.036). | Source → |
| Oxaliplatin Chemotherapy Less Effective in Colorectal Cancer with High WTAP Levels | Colorectal Cancer | lab-study | — | Source → |
| GL-V9 Enhances Effectiveness of Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Rare Side Effect of Cancer Drug: Transient Ischemic Attack | Colorectal Cancer | observational | — | Source → |
| Combination Therapy Shows Promise Against Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Study Examines Effectiveness of S-1 and Oxaliplatin in Treating Colorectal Liver Metastases | Colorectal Cancer | phase-2 | The disease-free survival (DFS) at 3 years was 52.9% in the low-dose group. | Source → |
| Researchers Identify Potential Biomarkers for Colorectal Cancer Resistance to Oxaliplatin | Colorectal Cancer | lab-study | — | Source → |
| Chemotherapy Sensitizes Colorectal Cancers to Immunotherapy | Colorectal Cancer | lab-study | — | Source → |
| Researchers Explore New Way to Deliver Cancer Drug | Colorectal Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.